Family Med Journals

Family Med

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Holgate S et al. - Based on clinical trial data analysis, it is recommended that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment should only be continued in responders, i.e. those judged by the physician to have achieved a marked improvement or complete asthma control. Omalizumab is generally well tolerated. Anaphylactic-like reactions are rare and less common than encountered with other biologics.

Related Articles

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy
International Archives of Allergy and Immunology, 10/21/09    Relevance Score: 87%

Relationship between pretreatment specific IgE and the response to omalizumab therapy
Allergy, 11/12/09    Relevance Score: 85%

Effects of omalizumab on markers of inflammation in patients with allergic asthma
Allergy, 11/16/09    Relevance Score: 84%

“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respiratory Medicine, 10/13/09    Relevance Score: 84%

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Allergy and Asthma Proceedings, 10/12/09    Relevance Score: 83%

Today in General Medicine...keeping you current

Changes in levels of haemoglobin A 1c during the first 6 years after diagnosis of clinical type 2 diabetes
Scandinavian Journal of Clinical and Laboratory Investigation, 12/10/09

Characteristics of sick-listing cases that physicians consider problematic - analyses of written case reports
Scandinavian Journal of Primary Health Care, 12/10/09

The Association Between the Number of Prescription Medications and Incident Falls in a Multi-ethnic Population of Adult Type-2 Diabetes Patients: The Diabetes and Aging Study
Journal of General Internal Medicine, 12/10/09